STERIS (NYSE:STE) Issues FY 2027 Earnings Guidance

STERIS (NYSE:STE) issued an update on its FY 2027 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 11.100-11.300 for the period, compared to the consensus estimate of 11.070. The company issued revenue guidance of $6.4 billion-$6.4 billion, compared to the consensus revenue estimate of $6.3 billion.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on STE. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 26th. Weiss Ratings downgraded STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, April 16th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $275.20.

STERIS Trading Down 2.7%

STERIS stock traded down $5.50 during midday trading on Monday, reaching $201.95. The stock had a trading volume of 1,002,126 shares, compared to its average volume of 773,329. The company has a quick ratio of 1.75, a current ratio of 2.48 and a debt-to-equity ratio of 0.26. The firm has a market cap of $19.81 billion, a price-to-earnings ratio of 28.17 and a beta of 0.95. STERIS has a 52-week low of $195.14 and a 52-week high of $269.44. The company has a fifty day moving average of $224.30 and a 200 day moving average of $244.27.

STERIS (NYSE:STE) last released its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). STERIS had a net margin of 12.15% and a return on equity of 14.34%. The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.59 billion. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. On average, analysts anticipate that STERIS will post 10.22 earnings per share for the current fiscal year.

STERIS Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be paid a $0.63 dividend. The ex-dividend date is Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. STERIS’s dividend payout ratio (DPR) is presently 35.15%.

Insider Buying and Selling at STERIS

In other news, Director Cynthia L. Feldmann sold 3,098 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total transaction of $734,876.58. Following the completion of the sale, the director directly owned 705 shares of the company’s stock, valued at approximately $167,233.05. The trade was a 81.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.07% of the company’s stock.

Institutional Investors Weigh In On STERIS

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. CTC Alternative Strategies Ltd. purchased a new stake in shares of STERIS in the fourth quarter valued at approximately $323,000. Vise Technologies Inc. increased its holdings in STERIS by 8.1% during the 4th quarter. Vise Technologies Inc. now owns 1,164 shares of the medical equipment provider’s stock worth $295,000 after purchasing an additional 87 shares during the period. Twinbeech Capital LP purchased a new position in STERIS during the 4th quarter worth $281,000. Walleye Trading LLC bought a new stake in STERIS during the 4th quarter valued at $274,000. Finally, Evergreen Capital Management LLC lifted its holdings in shares of STERIS by 11.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 1,005 shares of the medical equipment provider’s stock worth $241,000 after buying an additional 106 shares during the period. Institutional investors own 94.69% of the company’s stock.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.